{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:05:27Z","timestamp":1762506327055,"version":"3.40.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1093\/jjco\/hyu017","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T04:52:21Z","timestamp":1395723141000},"page":"435-441","source":"Crossref","is-referenced-by-count":5,"title":["Rapid Progression of Anemia Related to Tumor-lysis Syndrome Associated with Bortezomib Treatment in Myeloma Patients"],"prefix":"10.1093","volume":"44","author":[{"given":"Kazuhito","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakura","family":"Sakajiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,3,23]]},"reference":[{"key":"key\n\t\t\t\t20170511082009_HYU017C1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJM196303282681306","article-title":"Biochemistry of uric acid and its relation to gout","volume":"268","author":"Seegmiller","year":"1963","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511082009_HYU017C2","first-page":"7","article-title":"Acute tumor lysis syndrome","volume":"49","author":"Chasty","year":"1993","journal-title":"Br J Hosp Med"},{"key":"key\n\t\t\t\t20170511082009_HYU017C3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(01)90254-4","article-title":"Acute tumor lysis syndrome","volume":"28","author":"Altman","year":"2001","journal-title":"Semin Oncol"},{"key":"key\n\t\t\t\t20170511082009_HYU017C4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00024669-200201060-00004","article-title":"Hyperuricemia in patients with cancer","volume":"1","author":"Ribeiro","year":"2002","journal-title":"Am J Cancer"},{"key":"key\n\t\t\t\t20170511082009_HYU017C5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.12327","article-title":"Tumor lysis syndrome: current perspective","volume":"93","author":"Hochberg","year":"2008","journal-title":"Haematologica"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170511082009_HYU017C6","first-page":"386b","article-title":"Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma","volume":"102","author":"Mehta","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511082009_HYU017C7","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1592\/phco.2005.25.12.1820","article-title":"Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia","volume":"25","author":"Jaskiewicz","year":"2005","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20170511082009_HYU017C8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170511082009_HYU017C9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cario","year":"2004","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170511082009_HYU017C10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1651-2227.2006.00178.x","article-title":"Understanding diagnostictests 3: receiver operating characteristic curves","volume":"96","author":"Akobeng","year":"2007","journal-title":"Acta Paediatr"},{"key":"key\n\t\t\t\t20170511082009_HYU017C11","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170511082009_HYU017C12","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1046\/j.1365-2141.1999.01467.x","article-title":"Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma","volume":"105","author":"Fassas","year":"1999","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170511082009_HYU017C13","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20170511082009_HYU017C14","first-page":"S130","article-title":"Tumor-lysis syndrome after bortezomib treatment in refractory\/relapsed myeloma patients","volume":"96","author":"Tanimura","year":"2011","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20170511082009_HYU017C15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2362.1987.tb02197.x","article-title":"Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma","volume":"17","author":"Simmonsson","year":"1987","journal-title":"Eur J Clin Invest"},{"key":"key\n\t\t\t\t20170511082009_HYU017C16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-110-7-521","article-title":"High serum level of lactic dehydrogenase identify a high-grade lymphoma-like myeloma","volume":"110","author":"Barlogie","year":"1989","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170511082009_HYU017C17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.7326\/0003-4819-115-12-931","article-title":"High serum lactic dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma","volume":"115","author":"Dimopoulos","year":"1991","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170511082009_HYU017C18","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0301-472X(99)00105-8","article-title":"Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma","volume":"27","author":"Fossa","year":"1999","journal-title":"Exp Hematol"},{"key":"key\n\t\t\t\t20170511082009_HYU017C19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/hon.2900100209","article-title":"The biological and clinical significance of the Ki-67 growth fraction in multiple myeloma","volume":"10","author":"Drach","year":"1992","journal-title":"Hematol Oncol"},{"key":"key\n\t\t\t\t20170511082009_HYU017C20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000204847","article-title":"Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies","volume":"85","author":"Girino","year":"1991","journal-title":"Acta Haematol"},{"key":"key\n\t\t\t\t20170511082009_HYU017C21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V72.1.219.219","article-title":"Value of beta-2 microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed multiple myeloma","volume":"72","author":"Grippe","year":"1988","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511082009_HYU017C22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2141.1993.tb03058.x","article-title":"Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial","volume":"84","author":"Brown","year":"1993","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170511082009_HYU017C23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(25)00115-6","article-title":"Multiple myeloma: review of 869 cases","volume":"50","author":"Kyle","year":"1975","journal-title":"Mayo Clinic Proc"},{"key":"key\n\t\t\t\t20170511082009_HYU017C24","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0277-5379(91)90020-E","article-title":"Changing clinical presentation of multiple myeloma","volume":"27","author":"Riccardi","year":"1991","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20170511082009_HYU017C25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20170511082009_HYU017C26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.1997.tb01677.x","article-title":"Clinical recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokine and monitoring of erythropoiesis","volume":"58","author":"Musto","year":"1997","journal-title":"Eur J Haematol"},{"key":"key\n\t\t\t\t20170511082009_HYU017C27","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood.V99.4.1305","article-title":"Negative regulation of erythroblast maturation by Fas-L(+)\/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma","volume":"99","author":"Silvestris","year":"2002","journal-title":"Blood"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/44\/5\/435\/11686494\/hyu017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:25:18Z","timestamp":1746159918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article-lookup\/doi\/10.1093\/jjco\/hyu017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,23]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,3,23]]},"published-print":{"date-parts":[[2014,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyu017","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"type":"electronic","value":"1465-3621"},{"type":"print","value":"0368-2811"}],"subject":[],"published":{"date-parts":[[2014,3,23]]}}}